Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases

ConditionsBrain Metastases From Non-small Cell Lung Cancer (NSCLC)Brain Metastases From Melanoma Brain Metastases From Breast Cancer

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

AgeNot listed

SponsorThe Netherlands Cancer Institute

About this trial

This study aims to evaluate the diagnostic potential of 68-Gallium PSMA-PET/CT in stereotactic irradiated brain metastases from non-small cell lung cancer, melanoma and breast cancer.

Eligibility criteria

Qualifiers

Written informed consent

Age ≥ 18 years old

WHO PS 0-3

Measurable lesion ≥10mm according to RANO BM

Disqualifiers

Known allergy to Ga68-PSMA

Epileptic seizure less than 7 days before Ga68-PSMA PET/CT scan

Life expectancy less than 3 months

Patients with known prostate carcinoma

Trial design

Treatments tested in this trial

86-Gallium PSMA PET/CT

Treatment groups

100 Participants

are divided into 1 treatment group

Locations

Netherlands Cancer Institute - Antoni van Leeuwenhoek1066 CX Amsterdam, Amsterdam Netherlands

Sponsors and collaborators

The Netherlands Cancer Institute

Lead sponsor

Source ClinicalTrials.gov